Showing results (51-60 of 136) with videos related to
Sort By:
Pageof 14
British Journal of Cancer|February 22, 2017
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumoursRichard H Wilson, Tr Jeffry Evans, Mark R Middleton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrenceMiranda J Payne, Katerina Argyropoulou, Paul Lorigan, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 17, 2016
Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized TherapyJohn M Findlay, Kevin M Bradley, Lai Mun Wang, et al.The Lancet Regional Health. Europe|June 8, 2026
Diagnostic Implications of Multi-Cancer Early Detection Testing in the Investigation of Cancer Symptoms: An Exploratory Retrospective Analysis of the SYMPLIFY StudyAshley Jackson, Pradeep S Virdee, Sharon Tonner, et al.Cancer Chemotherapy and Pharmacology|February 21, 2013
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiationRuth Plummer, Paul Lorigan, Neil Steven, et al.Radiology Case Reports|September 28, 2018
Long-term radiological and histological outcomes following selective internal radiation therapy to liver metastases from breast cancerPaul C Lyon, Helen Winter, Karin Herbschleb, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatribAmanda J Watson, Ami Sabharwal, Mary Thorncroft, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid TumorsValentine M Macaulay, Mark R Middleton, S Gail Eckhardt, et al.Frontiers in Oncology|May 21, 2016
Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFRTamara Aleksic, Lisa Browning, Martha Woodward, et al.European Radiology|February 18, 2016
Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgeryJohn M Findlay, Richard S Gillies, James M Franklin, et al.Pageof 14